IBJNews

DailyMed sales trim Arcadia losses

Back to TopCommentsE-mailPrintBookmark and Share

Arcadia Resources Inc. narrowed its losses in its most recent quarter as it started to accelerate sales in its highly-touted DailyMed program, the company said today.

The Indianapolis-based provider of in-home health services and medical staffing lost $3.6 million, or 2 cents per share, on continuing operations in its fiscal first quarter, an improvement from a loss of $4 million, or 3 cents per share, in the same quarter a year ago.

Revenue for the three months ended June 30 fell slightly, to $26.4 million, compared with $26.8 million a year ago. Arcadia also reduced its debt by $7 million in the quarter.
Arcadia spent heavily on staffing and other costs as it took on a contract from Indianapolis-based WellPoint Inc. to offer its DailyMed service to 12,000 of the health insurer's Medicaid customers in Virginia.
DailyMed serves patients who take numerous medications by combining them into packets and marking them with time of day they must be taken. DailyMed also uses nurses and other staff to check up on patients.
DailyMed had sales last year of $6 million. But Arcadia officials believe sales will grow to a range of $25 million to $35 million by the end of the fiscal year ending in March 2010.
"We are excited to introduce DailyMed to WellPoint's Medicaid members and believe the result will help improve member care and lower health care costs by more effectively managing chronic medication utilization and reducing unnecessary hospitalizations for their Medicaid members," Arcadia CEO Marvin Richardson said in a prepared statement.
Revenue in Arcadia's other business unit - home health care and medical staff - fell 9 percent to $22.7 million.
 

ADVERTISEMENT

Post a comment to this story

COMMENTS POLICY
We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
 
You are legally responsible for what you post and your anonymity is not guaranteed.
 
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
 
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
 
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.
 

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
thisissue1-092914.jpg 092914

Subscribe to IBJ
ADVERTISEMENT